Advancing Drug Development.
Improving Lives. Together.

For 20 years, Critical Path Institute has been a trusted nonprofit that generates solutions to facilitate scientific and regulatory pathways that accelerate the development of therapies for people with unmet medical needs.

Our tools foster collaboration between scientific and regulatory bodies.

Tools
Platforms

Alzheimer’s Pre-dementia Clinical Trial Enrichment Tool

A quantitative clinical trial enrichment tool to help optimize clinical trial design in the pre-dementia stages of Alzheimer’s disease.

Alzheimer’s Disease Clinical Trial Simulation Tool

A clinical trial simulation tool to help optimize clinical trial design for mild and moderate AD.

DMD Clinical Trial Simulation (CTS) Tool

The Duchenne Muscular Dystrophy (DMD) CTS Tool optimizes clinical trial design of efficacy studies of potential therapies for DMD.

Early Motor Parkinson’s DAT Clinical Trial Enrichment Tool

A quantitative clinical trial enrichment tool to help optimize clinical trial design in the early-motor stages of Parkinson’s disease.

Islet Antibody Clinical Trial Enrichment Tool

This quantitative clinical trial enrichment tool helps optimize clinical trial design for therapies to prevent or delay diagnosis of T1D, using islet AAs with other relevant clinical features.

PRO Consortium Measures and Licensing

This platform delivers information regarding available measures covering different therapeutic areas.

Rare Disease Clinical Outcome Assessment Resource

The Rare Disease COA Resource provides information on published COAs that have the potential to be used to support efficacy endpoints in treatment trials for rare diseases.

See all tools & platforms

To make a difference for patients and their families.

“Critical Path for Alzheimer’s Disease is helping the industry by developing the tools that can help optimize clinical trial designs, identify individuals best suited for trials, and understand what are meaningful benefits for those diagnosed with early symptoms of AD. We need that perspective.”

Joe Montminy

Person Living with Younger-Onset Alzheimer's and Advocate for All People Living with Dementia

“Being a scientist, sometimes when you talk to people in other realms, it’s like speaking a different language. C-Path and the T1D Consortium is translating a lot of science talk into something actionable for those who are making decisions and can actually push these types of initiatives forward.”

Ryan Eberwine

Drug Discovery and Development Scientist, Person Living with T1D

“I hope that the Duchenne Regulatory Science Consortium (D-RSC) becomes more well known, and that everybody knows what kind of work they’re doing. I see a bright future ahead, and I see things being more accessible with the help of D-RSC. For anyone reading this, know that you can make a difference.”

Ryan Russell

PhD, Life Coach, Person Living with Duchenne Muscular Dystrophy

“Working with C-Path gives me so much hope because for the last 4.5 years of my advocacy and involvement in ALS Research and Clinical trial design, I’ve seen so many efforts that are disconnected and fragmented. Now I see this collaboration advancing therapeutic development for our disease.”

Phil Green

Person Living with ALS, Patient Advocate

“My initial impression of CP-RND is that it’s a fantastic opportunity for the ALS Community and others to play an important part in what I would call a dream team of the FDA, NIH, C-Path and patients that’s focused on accelerated development of powerful natural history data.”

Ron Bartek

Co-founder/President, Friedreich’s Ataxia Research Alliance

Our programs align the
medical community around
common goals.

Core Competencies

Our areas of expertise are essential to the tools we create.

Rare and Orphan Diseases

Pediatrics

Innovation in Translational Science and Biomarkers

Clinical Outcome Assessment

See all Programs

Advancing Drug Development.
Improving Lives. Together.

Our tools foster collaboration between scientific and regulatory bodies.

Alzheimer’s Pre-dementia Clinical Trial Enrichment Tool

Alzheimer’s Disease Clinical Trial Simulation Tool

DMD Clinical Trial Simulation (CTS) Tool

Early Motor Parkinson’s DAT Clinical Trial Enrichment Tool

Islet Antibody Clinical Trial Enrichment Tool

PRO Consortium Measures and Licensing

Rare Disease Clinical Outcome Assessment Resource

Critical Path for Alzheimer’s Disease Database

Duchenne Regulatory Science Consortium Database

Integrated Parkinson’s Database

The Multiple Sclerosis Outcome Assessments Consortium (MSOAC) Placebo Database

Polycystic Kidney Disease Outcomes Consortium Database

The Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®)

TB Platform for the Aggregation of Preclinical Experiments Data (TB-APEX)

TB Platform for Aggregation of Clinical TB Studies (TB-PACTS)

TB Platform for the Project to Accelerate New Treatments for Tuberculosis (PAN-TB)

To make a difference for patients and their families.

Joe Montminy

Ryan Eberwine

Ryan Russell

“Working with C-Path gives me so much hope because for the last 4.5 years of my advocacy and involvement in ALS Research and Clinical trial design, I’ve seen so many efforts that are disconnected and fragmented. Now I see this collaboration advancing therapeutic development for our disease.”

Phil Green

“My initial impression of CP-RND is that it’s a fantastic opportunity for the ALS Community and others to play an important part in what I would call a dream team of the FDA, NIH, C-Path and patients that’s focused on accelerated development of powerful natural history data.”

Ron Bartek

Our programs align the
medical community around
common goals.

Core Competencies

Neuroscience

Rare and Orphan Diseases

Pediatrics

Innovation in Translational Science and Biomarkers

Clinical Outcome Assessment

The impact is clear.

You can help advance drug development and improve lives.

Advancing Drug Development.Improving Lives. Together.

Our tools foster collaboration between scientific and regulatory bodies.

Alzheimer’s Pre-dementia Clinical Trial Enrichment Tool

Alzheimer’s Disease Clinical Trial Simulation Tool

DMD Clinical Trial Simulation (CTS) Tool

Early Motor Parkinson’s DAT Clinical Trial Enrichment Tool

Islet Antibody Clinical Trial Enrichment Tool

PRO Consortium Measures and Licensing

Rare Disease Clinical Outcome Assessment Resource

Critical Path for Alzheimer’s Disease Database

Duchenne Regulatory Science Consortium Database

Integrated Parkinson’s Database

The Multiple Sclerosis Outcome Assessments Consortium (MSOAC) Placebo Database

Polycystic Kidney Disease Outcomes Consortium Database

The Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®)

TB Platform for the Aggregation of Preclinical Experiments Data (TB-APEX)

TB Platform for Aggregation of Clinical TB Studies (TB-PACTS)

TB Platform for the Project to Accelerate New Treatments for Tuberculosis (PAN-TB)

To make a difference for patients and their families.

Joe Montminy

Ryan Eberwine

Ryan Russell

“Working with C-Path gives me so much hope because for the last 4.5 years of my advocacy and involvement in ALS Research and Clinical trial design, I’ve seen so many efforts that are disconnected and fragmented. Now I see this collaboration advancing therapeutic development for our disease.”

Phil Green

“My initial impression of CP-RND is that it’s a fantastic opportunity for the ALS Community and others to play an important part in what I would call a dream team of the FDA, NIH, C-Path and patients that’s focused on accelerated development of powerful natural history data.”

Ron Bartek

Our programs align the medical community around common goals.

Core Competencies

Neuroscience

Rare and Orphan Diseases

Pediatrics

Innovation in Translational Science and Biomarkers

Clinical Outcome Assessment

The impact is clear.

You can help advance drug development and improve lives.

Advancing Drug Development.
Improving Lives. Together.

Our programs align the
medical community around
common goals.